CTI BioPharma Income Statement

Financials in millions INR. Fiscal year is April - March.

Millions INR. Fiscal year is Apr - Mar.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	2017 - 2021
Period Ending	Jun '25 Jun 30, 2025	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022	Mar '21 Mar 31, 2021	2017 - 2021
Revenue	2,169,780	2,185,425	2,291,708	2,433,527	2,439,592	1,564,774	Upgrade
Revenue Growth (YoY)	-3.33%	-4.64%	-5.83%	-0.25%	55.91%	5.04%	Upgrade
Cost of Revenue	1,025,279	1,043,722	1,127,812	1,232,217	902,775	623,744	Upgrade
Gross Profit	1,144,501	1,141,703	1,163,896	1,201,310	1,536,817	941,030	Upgrade
Selling, General & Admin	250,206	248,890	245,096	253,428	259,364	221,573	Upgrade
Other Operating Expenses	637,887	644,024	696,118	641,383	629,226	432,177	Upgrade
Operating Expenses	994,396	997,127	1,040,036	988,163	979,598	746,087	Upgrade
Operating Income	150,106	144,576	123,860	213,148	557,219	194,943	Upgrade
Interest Expense	-74,167	-73,410	-75,076	-62,987	-54,622	-76,067	Upgrade
Interest & Investment Income	8,660	8,660	5,223	3,853	2,791	3,225	Upgrade
Earnings From Equity Investments	1,780	1,908	-579.8	4,181	6,492	3,273	Upgrade
Currency Exchange Gain (Loss)	4,195	4,195	420.3	16,578	-13,316	18,952	Upgrade
Other Non Operating Income (Expenses)	2,060	2,060	834.5	4,004	2,088	1,979	Upgrade
EBT Excluding Unusual Items	92,634	87,989	54,682	178,777	500,652	146,304	Upgrade
Merger & Restructuring Charges	-5,549	-6,340	-43,926	-936.4	-5,871	-3,561	Upgrade
Impairment of Goodwill	-	-	-	-	-	-1,172	Upgrade
Gain (Loss) on Sale of Investments	2,604	2,523	2,850	4,769	1,517	2,477	Upgrade
Gain (Loss) on Sale of Assets	2,902	2,879	10,126	-435.7	8,510	1,638	Upgrade
Asset Writedown	-1,192	-1,192	-35,203	177.5	-2,540	-7,251	Upgrade
Other Unusual Items	-367.7	-1,731	-	-	-	-	Upgrade
Pretax Income	91,031	84,129	-11,470	182,351	502,269	138,437	Upgrade
Income Tax Expense	48,406	52,391	37,626	101,598	84,776	56,539	Upgrade
Earnings From Continuing Operations	42,626	31,738	-49,096	80,754	417,493	81,898	Upgrade
Net Income to Company	42,626	31,738	-49,096	80,754	417,493	81,898	Upgrade
Minority Interest in Earnings	2,760	2,467	4,722	6,851	-15,954	-6,996	Upgrade
Net Income	45,386	34,205	-44,374	87,604	401,539	74,902	Upgrade
Preferred Dividends & Other Adjustments	-	-	-	-	10.9	1,814	Upgrade
Net Income to Common	45,386	34,205	-44,374	87,604	401,528	73,089	Upgrade
Net Income Growth	-	-	-	-78.18%	436.09%	381.21%	Upgrade
Shares Outstanding (Basic)	12,467	12,472	12,268	12,210	12,081	11,459	Upgrade
Shares Outstanding (Diluted)	12,470	12,475	12,271	12,214	12,091	11,460	Upgrade
Shares Change (YoY)	1.09%	1.66%	0.47%	1.02%	5.50%	0.10%	Upgrade
EPS (Basic)	3.64	2.74	-3.62	7.17	33.24	6.38	Upgrade
EPS (Diluted)	3.64	2.74	-3.62	7.17	33.21	6.38	Upgrade
EPS Growth	-	-	-	-78.41%	420.70%	437.90%	Upgrade
Free Cash Flow	-	78,413	20,941	75,406	338,588	373,481	Upgrade
Free Cash Flow Per Share	-	6.29	1.71	6.17	28.00	32.59	Upgrade
Dividend Per Share	-	3.600	3.600	3.600	5.100	2.500	Upgrade
Dividend Growth	-	-	-	-29.41%	104.00%	150.00%	Upgrade
Gross Margin	52.75%	52.24%	50.79%	49.36%	63.00%	60.14%	Upgrade
Operating Margin	6.92%	6.62%	5.41%	8.76%	22.84%	12.46%	Upgrade
Profit Margin	2.09%	1.57%	-1.94%	3.60%	16.46%	4.67%	Upgrade
Free Cash Flow Margin	-	3.59%	0.91%	3.10%	13.88%	23.87%	Upgrade
EBITDA	246,689	239,647	212,880	296,495	637,202	275,129	Upgrade
EBITDA Margin	11.37%	10.97%	9.29%	12.18%	26.12%	17.58%	Upgrade
D&A For EBITDA	96,583	95,071	89,020	83,347	79,982	80,185	Upgrade
EBIT	150,106	144,576	123,860	213,148	557,219	194,943	Upgrade
EBIT Margin	6.92%	6.62%	5.41%	8.76%	22.84%	12.46%	Upgrade
Effective Tax Rate	53.17%	62.28%	-	55.72%	16.88%	40.84%	Upgrade
Revenue as Reported	2,185,185	2,200,830	2,309,796	2,443,902	2,447,441	1,573,730	Upgrade

Updated Jan 27, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.